Similarly, in HNSCC PDOs, IGF2BP2 knockdown reversed PRMT1‐induced CBP resistance (Figure 4J; Figure S7D, Supporting Information). This evidence concerns the gene IGF2BP2 and head and neck squamous cell carcinoma.